- Home
- YI vs MAIA Comparison
YI vs MAIA Comparison
Compare YI & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YI
- MAIA
- Stock Information
- Founded
- YI 2010
- MAIA 2018
- Country
- YI China
- MAIA United States
- Employees
- YI N/A
- MAIA N/A
- Industry
- YI Retail-Drug Stores and Proprietary Stores
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- YI Consumer Staples
- MAIA Health Care
- Exchange
- YI Nasdaq
- MAIA Nasdaq
- Market Cap
- YI 60.7M
- MAIA 56.3M
- IPO Year
- YI N/A
- MAIA 2022
- Fundamental
- Price
- YI $5.71
- MAIA $1.54
- Analyst Decision
- YI
- MAIA
- Analyst Count
- YI 0
- MAIA 0
- Target Price
- YI N/A
- MAIA N/A
- AVG Volume (30 Days)
- YI 18.5K
- MAIA 353.0K
- Earning Date
- YI 08-28-2025
- MAIA 08-11-2025
- Dividend Yield
- YI N/A
- MAIA N/A
- EPS Growth
- YI N/A
- MAIA N/A
- EPS
- YI N/A
- MAIA N/A
- Revenue
- YI $1,984,717,013.00
- MAIA N/A
- Revenue This Year
- YI N/A
- MAIA N/A
- Revenue Next Year
- YI N/A
- MAIA N/A
- P/E Ratio
- YI N/A
- MAIA N/A
- Revenue Growth
- YI N/A
- MAIA N/A
- 52 Week Low
- YI $4.15
- MAIA $1.40
- 52 Week High
- YI $11.90
- MAIA $3.74
- Technical
- Relative Strength Index (RSI)
- YI 30.89
- MAIA 47.28
- Support Level
- YI $5.35
- MAIA $1.46
- Resistance Level
- YI $7.07
- MAIA $1.56
- Average True Range (ATR)
- YI 0.48
- MAIA 0.09
- MACD
- YI -0.13
- MAIA 0.00
- Stochastic Oscillator
- YI 16.75
- MAIA 27.59
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.